Clinical Trial

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-11-10; most recent amendment 2025-07-28.
Status change: Recruiting → Active, Not Recruiting 2024-09-05
Status change: Not Yet Recruiting → Recruiting 2022-11-18
Trial Details
NCT Number NCT05617755
Lead Sponsor Arsenal Biosciences, Inc.
Conditions Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm +1 more
Enrollment 19 participants
Start Date 2022-11-29
Primary Completion 2024-09-30 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-07-30